Velneperit
 | |
| Clinical data | |
|---|---|
| ATC code | None |
| Identifiers | |
| |
| CAS Number | 342577-38-2 |
| PubChem (CID) | 20629114 |
| ChemSpider | 25948511 |
| Chemical and physical data | |
| Formula | C17H24F3N3O3S |
| Molar mass | 407.451 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Velneperit (S-2367) is a drug developed by Shionogi, which acts as a potent and selective antagonist for the Neuropeptide Y receptor Y5. It has anorectic effects and was developed as a possible treatment for obesity, but was discontinued from further development after disappointing results in Phase II clinical trials. However it was still considered a successful proof of concept of the potential of Y5 receptor antagonists as possible anti-obesity agents in future.[1][2][3]
References
- ↑ Yukioka H. A potent and selective neuropeptide Y Y5-receptor antagonist, S-2367, as an anti-obesity agent. (Japanese). Nihon Yakurigaku Zasshi. 2010 Nov;136(5):270-4. PMID 21079365
- ↑ Oda S, et al. Development of an Optimized Synthetic and Purification Process of S-2367 (Velneperit), a Novel Neuropeptide Y (NPY) Y5 Receptor Antagonist. Org. Process Res. Dev. 2015; 19(4):531–536. doi: 10.1021/acs.oprd.5b00023
- ↑ George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):65-76. doi: 10.1177/1074248413501017 PMID 24064009
This article is issued from Wikipedia - version of the 10/31/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.